EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Real‐world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan

Yuki Kita iD, Hikari Otsuka, Katsuhiro Ito iD, Takuto Hara iD, Soichiro Shimura, Takashi Kawahara iD, Minoru Kato, Sojun Kanamaru, Koji Inoue, Hiroki Ito, Atsushi Igarashi, Tomokazu Sazuka iD und 9 weitere

International Journal of Urology · 2024

DOI: 10.1111/iju.15411 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Urology, 2024. Verfasst von Yuki Kita und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: Carcinoma, Transitional Cell. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Immune checkpoint inhibitors and enfortumab vedotin have opened new avenues for sequential treatment strategies for locally advanced/metastatic urothelial carcinoma (la/mUC). In the pre‐enfortumab vedotin era, many patients could not receive third‐line treatment owing to rapid disease progression and poor general status. This study aimed to analyze real‐world sequential treatment practices for la/mUC in Japan, with a focus on patients who do not receive third‐line treatment.

Methods

We analyzed data for 1023 la/mUC patients diagnosed between January 2020 and December 2021 at 54 institutions from a Japanese nationwide cohort.

Results

At the median follow‐up of 28.5 months, the median overall survival from first‐line initiation for 905 patients who received systemic anticancer treatment was 19.1 months. Among them, 81% and 32% received second‐ and third‐line treatment. Notably, 52% had their treatment terminated before the opportunity for third‐line treatment. Multivariate logistic regression analysis revealed that low performance status (≥1), elevated neutrophil‐to‐lymphocyte ratio (≥3), and low body mass index (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Transitional CellAgedAged, 80 and overFemaleHumansMaleMiddle AgedDisease ProgressionImmune Checkpoint InhibitorsJapanPractice Patterns, Physicians'Retrospective StudiesTreatment OutcomeUrinary Bladder NeoplasmsUrologic NeoplasmsCohort Studies

Stichwörter der Autor:innen

chemotherapyenfortumab vedotinimmune checkpoint inhibitorsequential treatmenturothelial carcinoma

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Department of Urology, Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan.
  • Department of Urology, Kobe University, Kobe, Japan.
  • Department of Urology, Kitasato University, Tokyo, Japan.
  • Department of Urology, University of Tsukuba, Tsukuba, Japan.
  • Department of Urology, Osaka Metropolitan University, Osaka, Japan.

ORCID-Profile: Yuki Kita, Katsuhiro Ito, Takuto Hara, Takashi Kawahara, Tomokazu Sazuka, Kohei Hashimoto, Takashige Abe, Sei Naito, Takashi Kobayashi

Zitieren

APA

Kita, Y., Otsuka, H., Ito, K., Hara, T., Shimura, S., Kawahara, T., Kato, M., Kanamaru, S., Inoue, K., Ito, H., Igarashi, A., Sazuka, T., Takamatsu, D., Hashimoto, K., Abe, T., Naito, S., Matsui, Y., Nishiyama, H., Kitamura, H., …, & Japan Urological Oncology Group (2024). Real‐world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan. International Journal of Urology. https://doi.org/10.1111/iju.15411

Vancouver

Kita Y, Otsuka H, Ito K, Hara T, Shimura S, Kawahara T, et al. Real‐world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan. International Journal of Urology. 2024. doi:10.1111/iju.15411

BibTeX
@article{Kita2024,
  author = {Kita, Yuki and Otsuka, Hikari and Ito, Katsuhiro and Hara, Takuto and Shimura, Soichiro and Kawahara, Takashi and Kato, Minoru and Kanamaru, Sojun and Inoue, Koji and Ito, Hiroki and Igarashi, Atsushi and Sazuka, Tomokazu and Takamatsu, Dai and Hashimoto, Kohei and Abe, Takashige and Naito, Sei and Matsui, Yoshiyuki and Nishiyama, Hiroyuki and Kitamura, Hiroshi and Kobayashi, Takashi and Japan Urological Oncology Group, Japan Urological Oncology Group},
  title = {Real‐world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan},
  journal = {International Journal of Urology},
  year = {2024},
  doi = {10.1111/iju.15411}
}
Kostenlos starten →